LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC₅₀ of 0.079 μM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC.

Solid

IC₅₀: 0.079 μM (EphB3)

Room temperature or refrigerated transportation.

• [1]. Qiao L, et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6122-6.  [Information]

  [2]. Park SH, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics. 2019 Apr 12;9(8):2235-2251.  [Information]